Can integration of Alzheimer’s plasma biomarkers with MRI, cardiovascular, genetics, and lifestyle measures improve cognition prediction?
Robel K Gebre(Mayo Clinic), Prashanthi Vemuri(Mayo Clinic in Arizona), Jonathan Graff‐Radford(Mayo Clinic), Maria Vassilaki(Mayo Clinic), Jeffrey L. Gunter(Mayo Clinic in Arizona), Ekaterina I. Hofrenning(Mayo Clinic in Florida), Scott A. Przybelski(Mayo Clinic in Florida), Vijay K. Ramanan(Mayo Clinic in Arizona), Mary M. Machulda(Mayo Clinic), Alicia Algeciras‐Schimnich(Mayo Clinic), Ronald C. Petersen(Mayo Clinic in Arizona), Aivi T. Nguyen(Mayo Clinic), Timothy G. Lesnick(Mayo Clinic in Florida), David S. Knopman(Mayo Clinic), Val J. Lowe(Mayo Clinic), Sheelakumari Raghavan(Mayo Clinic), Clifford R. Jack(Mayo Clinic)
Cited by 6
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment as a diagnostic entity
|Journal of Internal Medicine|2004|7.8k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k